AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8646611 — intervention group
Group type: COMPARATOR
Intervention: Dual task condition (secondary task while instructing)
Number of subjects: 45
Study 2288835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) alone
Number of subjects: 9
Study 2288835 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg) after pretreatment with oral co-trimoxazole
Number of subjects: 9
Study 6352641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 50
Study 6352641 — intervention group
Group type: COMPARATOR
Intervention: Combination of azlocillin and tobramycin
Number of subjects: 50
Study 30608620 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 0
Study 30608620 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 28442195 — intervention group
Group type: EXPERIMENTAL
Intervention: Research and Religion
Number of subjects: 129
Study 28442195 — intervention group
Group type: COMPARATOR
Intervention: Research Only
Number of subjects: 129
Study 28442195 — intervention group
Group type: COMPARATOR
Intervention: Religion Only
Number of subjects: 129
Study 26509561 — intervention group
Group type: EXPERIMENTAL
Intervention: Study arm II (physician aware of study participation)
Number of subjects: 120
Study 26509561 — intervention group
Group type: COMPARATOR
Intervention: Study arm I (physician unaware of study participation)
Number of subjects: 120
Study 26509561 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 120
Study 26509561 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in study arm II
Number of subjects: 120
Study 24136801 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS TKA with complete infrapatellar fat pad excision
Number of subjects: 90
Study 24136801 — intervention group
Group type: COMPARATOR
Intervention: MIS TKA without infrapatellar fat pad excision
Number of subjects: 90
Study 24136801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 22516668 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (phase 2E)
Number of subjects: 0
Study 22516668 — intervention group
Group type: COMPARATOR
Intervention: Untried atypical antipsychotic (phase 2E)
Number of subjects: 0
Study 19408475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized collagen bone substitute (MCBS) combined with recombinant human platelet-derived growth factor-BB (0.3 mg/mL)
Number of subjects: 7
Study 17761236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition computer modules (oral rehydration therapy, calcium, and vitamins) on compact disc for study over 6 weeks
Number of subjects: 38
Study 17761236 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 15119693 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 97
Study 15119693 — intervention group
Group type: COMPARATOR
Intervention: 20 mg simvastatin
Number of subjects: 97
Study 11766367 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide alone (group I)
Number of subjects: 102
Study 11766367 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide and Estramustine (group II)
Number of subjects: 102
Study 11766367 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine alone (group III)
Number of subjects: 102
Study 9489910 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal pouch (Pouch group)
Number of subjects: 46
Study 9489910 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction (Roux-en-Y group)
Number of subjects: 46
Study 9489910 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe dumping (compared to those without dumping)
Number of subjects: 46
Study 9489910 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal hydrogen concentration in the glucose breath test
Number of subjects: 46
Study 7848228 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg prostaglandin F2 alpha (PGF2 alpha) applied intracervically
Number of subjects: 296
Study 7848228 — intervention group
Group type: COMPARATOR
Intervention: Standard oxytocin intravenous infusion
Number of subjects: 296
Study 2899425 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive treatments (ECTs)
Number of subjects: 34
Study 2899425 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate
Number of subjects: 34
Study 2899425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ECT and Lithium carbonate
Number of subjects: 34
Study 31473019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous contrast exposure
Number of subjects: 0
Study 29452259 — intervention group
Group type: EXPERIMENTAL
Intervention: AsthmaCare mobile application
Number of subjects: 193
Study 29452259 — intervention group
Group type: COMPARATOR
Intervention: Control (online asthma information)
Number of subjects: 193
Study 27903675 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant multiagent chemotherapy
Number of subjects: 63
Study 27903675 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 63
Study 27903675 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant endocrine therapy only or no adjuvant systemic therapy
Number of subjects: 63
Study 27903675 — intervention group
Group type: COMPARATOR
Intervention: (Neo)adjuvant chemotherapy
Number of subjects: 63
Study 25820464 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA-VC
Number of subjects: 14
Study 25820464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22618308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 90
Study 22618308 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (Treatment as Usual - TAU)
Number of subjects: 90
Study 21177797 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg soy hypocotyl isoflavones
Number of subjects: 403
Study 21177797 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg soy hypocotyl isoflavones
Number of subjects: 403
Study 21177797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 403
Study 18978622 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw clenching (JAW)
Number of subjects: 14
Study 18978622 — intervention group
Group type: COMPARATOR
Intervention: Non-jaw clenching (NON‐JAW)
Number of subjects: 14
Study 16187969 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT (bismuth biskalcitrate, metronidazole, tetracycline) in fed state
Number of subjects: 23
Study 16187969 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT (bismuth biskalcitrate, metronidazole, tetracycline) in fasting state
Number of subjects: 23
Study 16187969 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT (bismuth biskalcitrate, metronidazole, tetracycline) administered with food
Number of subjects: 23
Study 12792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Group drug counseling (GDC)
Number of subjects: 487
Study 12792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling plus individual drug counseling (IDC)
Number of subjects: 487
Study 12792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 487
Study 12792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy (SE)
Number of subjects: 487
Study 12792359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IDC and GDC
Number of subjects: 487
Study 12792359 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 487
Study 10669989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (omeprazole 20 mg b.d. plus amoxycillin 1 g b.d.)
Number of subjects: 83
Study 10669989 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole 20 mg b.d., clarithromycin 250 mg b.d., and tetracycline 500 mg b.d.)
Number of subjects: 83
Study 10669989 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with triple regimen
Number of subjects: 83
Study 10669989 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with dual therapy
Number of subjects: 83
Study 8549172 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of new respiratory symptoms (dyspnea)
Number of subjects: 446
Study 8549172 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of new respiratory symptoms (wheeze)
Number of subjects: 446
Study 8549172 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of respiratory symptoms
Number of subjects: 446
Study 8549172 — intervention group
Group type: COMPARATOR
Intervention: Initially reported symptoms
Number of subjects: 446
Study 1985140 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminders
Number of subjects: 7397
Study 1985140 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reminders
Number of subjects: 7397
Study 1985140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both physician and patient reminders
Number of subjects: 7397
Study 1985140 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7397
Study 6339026 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy plus internal mammary dissection
Number of subjects: 1453
Study 6339026 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy without internal mammary dissection
Number of subjects: 1453
Study 30552829 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.075 mmol/kg)
Number of subjects: 104
Study 30552829 — intervention group
Group type: COMPARATOR
Intervention: Gadoterate meglumine (0.15 mmol/kg)
Number of subjects: 104
Study 30316489 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-based cognitive behavioral therapy (ACBT)
Number of subjects: 51
Study 30316489 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive behavioral therapy (CCBT)
Number of subjects: 51
Study 30316489 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 51
Study 26970112 — intervention group
Group type: EXPERIMENTAL
Intervention: License condition (self-licensing)
Number of subjects: 218
Study 26970112 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no self-licensing)
Number of subjects: 218
Study 25026919 — intervention group
Group type: EXPERIMENTAL
Intervention: Black chokeberry juice (156 mL per resident daily for 3 months in group A)
Number of subjects: 236
Study 25026919 — intervention group
Group type: EXPERIMENTAL
Intervention: Black chokeberry juice (89 mL per resident daily for 3 months in group B)
Number of subjects: 236
Study 25026919 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (for 3 months in group A)
Number of subjects: 236
Study 25026919 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (for 3 months in group B)
Number of subjects: 236
Study 22261573 — intervention group
Group type: EXPERIMENTAL
Intervention: HiCarb/LoProt diet (glucose 10 mg · kg(‐1) · min(‐1)/protein 0.7 g · kg(‐1) · d(‐1))
Number of subjects: 24
Study 22261573 — intervention group
Group type: EXPERIMENTAL
Intervention: HiCarb/LoProt diet
Number of subjects: 24
Study 22261573 — intervention group
Group type: COMPARATOR
Intervention: NormCarb/LoProt diet (glucose 7.5 mg · kg(‐1) · min(‐1)/protein 0.3 g · kg(‐1) · d(‐1))
Number of subjects: 24
Study 22261573 — intervention group
Group type: COMPARATOR
Intervention: NormCarb/LoProt diet
Number of subjects: 24
Study 20039931 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban with enoxaparin
Number of subjects: 60
Study 20039931 — intervention group
Group type: COMPARATOR
Intervention: High-dose tirofiban with unfractionated heparin (UFH)
Number of subjects: 60
Study 17116121 — intervention group
Group type: EXPERIMENTAL
Intervention: Unannounced visits by standardized patients (SPs) portraying roles with major depression or adjustment disorder.
Number of subjects: 152
Study 17116121 — intervention group
Group type: EXPERIMENTAL
Intervention: High suspicion visits
Number of subjects: 152
Study 17116121 — intervention group
Group type: COMPARATOR
Intervention: HMO settings
Number of subjects: 152
Study 17116121 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients (SPs)
Number of subjects: 152
Study 12702111 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth neighbouring cleft (site 1)
Number of subjects: 75
Study 12702111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth in cleft (site 2)
Number of subjects: 75
Study 12702111 — intervention group
Group type: COMPARATOR
Intervention: Contra-lateral teeth (sites 3 and 4)
Number of subjects: 75
Study 10896692 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG coherence analysis in patients with multiple sclerosis
Number of subjects: 28
Study 10896692 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (22 subjects)
Number of subjects: 28
Study 8816002 — intervention group
Group type: EXPERIMENTAL
Intervention: Health examination programme
Number of subjects: 124
Study 8816002 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health examination)
Number of subjects: 124
Study 1401823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 18
Study 1401823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 18
Study 4058845 — intervention group
Group type: EXPERIMENTAL
Intervention: Honan intraocular pressure reducer (HIPR) applied for 40 minutes
Number of subjects: 0
Study 4058845 — intervention group
Group type: COMPARATOR
Intervention: Honan intraocular pressure reducer (HIPR) applied for 5 minutes
Number of subjects: 0
Study 30469101 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐STOPS (Electronic Support Tool and Orders for the Prevention of Smoking)
Number of subjects: 126
Study 30469101 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐STOPS
Number of subjects: 126
Study 30212434 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 331
Study 30212434 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemsex
Number of subjects: 331
Study 30212434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk sexual practices
Number of subjects: 331
Study 27648752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for SAD
Number of subjects: 20
Study 27648752 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 20
Study 27648752 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 25081864 — intervention group
Group type: COMPARATOR
Intervention: Catholic hospital
Number of subjects: 236
Study 25081864 — intervention group
Group type: COMPARATOR
Intervention: Secular hospital
Number of subjects: 236
Study 25081864 — intervention group
Group type: COMPARATOR
Intervention: Gynecologist care
Number of subjects: 236
Study 22575023 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidiary support system initiated and coordinated by a dementia care manager (nurse with dementia-specific qualifications)
Number of subjects: 0
Study 22575023 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20395096 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5 g/day for 8 weeks)
Number of subjects: 33
Study 20395096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg of vitamin C)
Number of subjects: 33
Study 18555812 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mcg ethinyl estradiol plus 3 mg drospirenone (Group A)
Number of subjects: 65
Study 18555812 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg ethinyl estradiol plus 3 mg drospirenone (Group B)
Number of subjects: 65
Study 18555812 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (Group C)
Number of subjects: 65
Study 16003231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 200
Study 16003231 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 200
Study 12484508 — intervention group
Group type: COMPARATOR
Intervention: CCB (amlodipine 5 mg once daily)
Number of subjects: 17
Study 12484508 — intervention group
Group type: COMPARATOR
Intervention: ACE‐I (temocapril 2 mg once daily)
Number of subjects: 17
Study 12484508 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (candesartan 4 mg once daily) added to CCB
Number of subjects: 17
Study 12484508 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (candesartan 4 mg once daily) added to ACE‐I
Number of subjects: 17
Study 12484508 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB plus ACE‐I
Number of subjects: 17
Study 10717757 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine 30 mg/kg
Number of subjects: 364
Study 10717757 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 25 mg/kg
Number of subjects: 364
Study 7491391 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of Methylphenidate (MPH)
Number of subjects: 6
Study 7491391 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg of Methylphenidate (MPH)
Number of subjects: 6
Study 7491391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1834462 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0.5 mg)
Number of subjects: 23
Study 1834462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml solvent)
Number of subjects: 23
Study 7042357 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (800 mg/day)
Number of subjects: 97
Study 7042357 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg/day)
Number of subjects: 97
Study 30155870 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis (moderate or severe)
Number of subjects: 405078
Study 30155870 — intervention group
Group type: COMPARATOR
Intervention: No psoriasis
Number of subjects: 405078
Study 31090747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mm subcrestal implant placement
Number of subjects: 60
Study 31090747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mm subcrestal implant placement
Number of subjects: 60
Study 28873376 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg cathine
Number of subjects: 241
Study 28873376 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg cathine
Number of subjects: 241
Study 28873376 — intervention group
Group type: EXPERIMENTAL
Intervention: 53.3 mg cathine
Number of subjects: 241
Study 28873376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 26445024 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape (KT) applied to the volar aspect of the dominant forearm
Number of subjects: 13
Study 26445024 — intervention group
Group type: COMPARATOR
Intervention: No tape applied
Number of subjects: 13
Study 23506844 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula (pHF-W)
Number of subjects: 2252
Study 23506844 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula (eHF-W)
Number of subjects: 2252
Study 23506844 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula (eHF-C)
Number of subjects: 2252
Study 23506844 — intervention group
Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 2252
Study 21153030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L: -arginine (10 g in 20 min)
Number of subjects: 20
Study 21153030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 21153030 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (placebo and arginine)
Number of subjects: 20
Study 19717547 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IFN-alpha IU/day
Number of subjects: 84
Study 19717547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IFN-alpha IU/day
Number of subjects: 84
Study 19717547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 17092979 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day donepezil
Number of subjects: 24
Study 17092979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15596568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 701
Study 15596568 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 701
Study 11139914 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-eluting coronary venous leads
Number of subjects: 58
Study 9377534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford Sleep Resistance test (OSLER test)
Number of subjects: 20
Study 9377534 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of Wakefulness Test (MWT)
Number of subjects: 20
Study 8436777 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1600 micrograms/day for 14 days)
Number of subjects: 10
Study 3759282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg every 6 h)
Number of subjects: 22
Study 3759282 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg every 6 h)
Number of subjects: 22
Study 31000010 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete FFR-guided revascularization
Number of subjects: 280
Study 31000010 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only PCI
Number of subjects: 280
Study 29548945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 29548945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26906129 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 101
Study 26906129 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal communication with physicians
Number of subjects: 101
Study 26906129 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 101
Study 26906129 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in treatment decision making
Number of subjects: 101
Study 26906129 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial difficulty
Number of subjects: 101
Study 26906129 — intervention group
Group type: EXPERIMENTAL
Intervention: Social functioning
Number of subjects: 101
Study 24581132 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (lower remifentanil concentration)
Number of subjects: 48
Study 24581132 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (higher remifentanil concentration)
Number of subjects: 48